KALA BIO, Inc. (KALA)
NASDAQ: KALA · Real-Time Price · USD
0.3850
-0.0344 (-8.20%)
At close: Oct 2, 2026, 4:00 PM EDT
0.3785
-0.0065 (-1.69%)
After-hours: Oct 2, 2026, 7:51 PM EDT
KALA BIO Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
7.45M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 3.89M | -7.35M | -65.37% |
| Dec 31, 2021 | 11.24M | 4.88M | 76.67% |
| Dec 31, 2020 | 6.36M | 288.00K | 4.74% |
| Dec 31, 2019 | 6.07M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 45.00K | -410.00K | -90.11% |
| Dec 31, 2014 | 455.00K | 405.00K | 810.00% |
| Dec 31, 2013 | 50.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ensysce Biosciences | 4.50M |
| Traws Pharma | 2.73M |
| Longeveron | 1.19M |
| Exicure | 500.00K |
| Azitra | 7.50K |
| Aprea Therapeutics | 5.19K |
| Soligenix | 2.34K |
KALA News
- 3 days ago - KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception - Newsfile Corp
- 8 days ago - KALA BIO Proxy statement: Proxy filing - Filings
- 8 days ago - Kala Bio, Virotek sign letter of intent with U.S. DNA testing platform - TheFly
- 8 days ago - Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products - GlobeNewsWire
- 15 days ago - KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team - GlobeNewsWire
- 21 days ago - KALA BIO Proxy statement: Proxy filing - Filings
- 4 weeks ago - Kala Bio, Virotek announce exclusive distribution and reseller agreement - TheFly
- 4 weeks ago - Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program - GlobeNewsWire